4.11
Mural Oncology Plc stock is traded at $4.11, with a volume of 227.45K.
It is down -2.84% in the last 24 hours and down -3.75% over the past month.
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
See More
Previous Close:
$4.23
Open:
$4.23
24h Volume:
227.45K
Relative Volume:
1.45
Market Cap:
$70.81M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+10.19%
1M Performance:
-3.75%
6M Performance:
+18.79%
1Y Performance:
-9.07%
Mural Oncology Plc Stock (MURA) Company Profile
Name
Mural Oncology Plc
Sector
Industry
Phone
353 1 905 8020
Address
10 EARLSFORT TERRACE, DUBLIN 2
Compare MURA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
MURA
Mural Oncology Plc
|
4.11 | 70.81M | 0 | 0 | 0 | 0.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
512.52 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
672.36 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
619.97 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
253.44 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
266.26 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Mural Oncology Plc Stock (MURA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
Apr-04-24 | Initiated | Morgan Stanley | Overweight |
Mural Oncology Plc Stock (MURA) Latest News
Q1 EPS Estimates for Mural Oncology Reduced by HC Wainwright - Defense World
HC Wainwright Reiterates Buy Rating for Mural Oncology (NASDAQ:MURA) - Defense World
Mural Oncology enters agreement for share sales By Investing.com - Investing.com South Africa
Mural Oncology enters agreement for share sales - Investing.com
Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones - The Manila Times
Mural Oncology Slashes Losses by 42% as Two Major Cancer Trial Results Approach - StockTitan
Mural Oncology CEO Caroline Loew sells shares worth $14,491 - Investing.com
Mural oncology officer sells shares worth $9,308 - Investing.com India
Mural oncology officer sells shares worth $9,308 By Investing.com - Investing.com South Africa
Mural Oncology's chief medical officer sells $51,293 in shares - Investing.com India
Mural Oncology’s chief medical officer sells $51,293 in shares - Investing.com
Exclusive: Mural Oncology Unveils Next-Gen Cancer Treatment Strategy at Major Healthcare Conference - StockTitan
Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times
Mural Oncology plc (NASDAQ:MURA) Short Interest Update - MarketBeat
Alkermes plc (ALKS) reports earnings - Quartz
We Think Mural Oncology (NASDAQ:MURA) Needs To Drive Business Growth Carefully - Yahoo Finance
Mural Oncology (NASDAQ:MURA) Trading 8.8% HigherHere's What Happened - MarketBeat
Mural Oncology (NASDAQ:MURA) Trading 8.8% Higher – Here’s Why - Defense World
Jones Trading sets $16 target on Mural Oncology stock By Investing.com - Investing.com Nigeria
This Vital Farms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Geode Capital Management LLC Purchases 4,731 Shares of Mural Oncology plc (NASDAQ:MURA) - Defense World
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts - The Manila Times
Mural Oncology Expands Pipeline with Two Novel Cancer Therapies, Advances Key Clinical Trials - StockTitan
Mural Oncology's chief legal officer sells $8,354 in shares By Investing.com - Investing.com Australia
Mural Oncology's chief legal officer sells $8,354 in shares - Investing.com India
Fmr LLC Grows Stake in Mural Oncology plc (NASDAQ:MURA) - Defense World
2025 will be a big year for Mural Oncology's drugs in development - The Business Journals
BNP Paribas Financial Markets Lowers Stake in Mural Oncology plc (NASDAQ:MURA) - Defense World
Mural Oncology stock hits 52-week low at $2.87 By Investing.com - Investing.com UK
Mural Oncology CEO Caroline Loew sells shares worth $9,394 - Investing.com
Mural Oncology CEO Caroline Loew sells shares worth $9,394 By Investing.com - Investing.com UK
Mural Oncology plc (NASDAQ:MURA) Shares Sold by Verition Fund Management LLC - MarketBeat
Mural Oncology GAAP EPS of -$1.84; reaffirms financial guidance - MSN
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Mural Oncology Awards Key Talent with Stock Options and RSU Inducement Grants - StockTitan
Analysts Give Strong Buy Rating To This Undervalued Medical Stock (MURA) With Up To 350% Of Share Price Upside - Benzinga
Alkermes to Participate in Upcoming Investor Conferences - Quantisnow
Raymond James Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks - Yahoo Finance
Rodman & Renshaw Initiates Coverage of Mural Oncology (MURA) with Buy Recommendation - MSN
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer - The Manila Times
Mural Oncology's Cancer Drug Shows 33% Response Rate in Melanoma Trial Data | MURA Stock News - StockTitan
HC Wainwright Raises Earnings Estimates for Mural Oncology - Defense World
HC Wainwright Predicts Stronger Earnings for Mural Oncology - MarketBeat
MURAMural Oncology plc Ordinary Shares Latest Stock News & Market Updates - StockTitan
Armistice Capital, LLC Increases Stake in Mural Oncology PLC - GuruFocus.com
Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress - The Manila Times
Mural Oncology plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Mural Oncology Reports 38% Lower Net Loss, Hits Trial Enrollment Milestones in Q3 | MURA Stock News - StockTitan
Mural Oncology Plc Stock (MURA) Financials Data
There is no financial data for Mural Oncology Plc (MURA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):